Skip to content

Effects of Different Local Medications on Sore Throat After Endotracheal Intubation: A Single-Center Randomized Controlled Trial

Effects of Different Local Medications on Sore Throat After Endotracheal Intubation: A Single-Center Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500110178
Enrollment
Unknown
Registered
2025-10-09
Start date
2024-10-05
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative sore throat

Interventions

Lidocaine Group (Group L):Prior to intubation, 5 mL of 2% lidocaine was applied topically to the glottis and airway
Ropivacaine Group (Group P):Prior to intubation, 5 mL of 0.75% ropivacaine was applied topically to the glottis and airway

Sponsors

General Hospital of Eastern Theater Command
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients scheduled for elective non-cardiovascular, non-pulmonary, non-neck surgeries under general anesthesia with oral endotracheal intubation; 2. ASA class I, II, or III; 3. Age >=18 years; 4. BMI between 18.5 and <28 kg/m^2.

Exclusion criteria

Exclusion criteria: 1. Acute or chronic respiratory diseases; 2. Patients with a history of smoking who quit less than 4 weeks ago; 3. History of previous neck or airway surgery; 4. History of chronic pharyngitis, sore throat, or hoarseness; 5. History of gastroesophageal reflux disease; 6. Predicted difficult intubation; 7. More than two failed intubation attempts or intubation requiring assistance with devices (e.g., fiberoptic bronchoscope); 8. Heart dysfunction (NYHA class III or above, congestive heart failure, various types of arrhythmias, etc.); 9. Liver or kidney dysfunction; 10. Inability to cooperate with data collection due to vision, hearing, or other impairments; 11. Allergy to the study drugs (e.g., amide local anesthetics).

Design outcomes

Primary

MeasureTime frame
Incidence and severity of sore throat at 2 minutes after extubation;

Secondary

MeasureTime frame
Incidence of sore throat at 30 minutes after extubation;The incidence of sore throat at PACU discharge;The incidence of sore throat at 24h;Incidence of cough during extubation;Incidence of hoarseness assessed at 5 min post-extubation;Incidence of hoarseness assessed at 30 min post-extubation;The incidence of hoarseness at 24 hours postoperatively;Incidence of postintubation hypertension;Incidence of postoperative pulmonary complications (PPCs) during hospitalization;Throat comfort at 5 minutes after extubation.;Throat comfort at 30 minutes after extubation.;Throat comfort at pacu discharge;Throat comfort at 24 hours postoperatively;The dosage of vasoactive drugs during the intubation period;The dosage of vasoactive drugs during the extubation period;Adverse reactions caused by local anesthetic at 24 h postextubation;Blood pressure during intubation;Heart rate during intubation;Blood pressure during extubation;Heart rate during extubation;Incisional NRS score at 5 minutes after extubation;Incisional NRS score at 30 minutes after extubation;Incisional NRS score at pacu discharge;The incidence of hypotension between anesthesia induction and surgical incision;

Countries

China

Contacts

Public ContactKangli Hui

General Hospital of Eastern Theater Command

17756702256@163.com+86 177 5670 2256

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026